ASTRAZENECA PLC-SPONS ADR (AZN)

3 Blue-Chip Stocks to Buy as High Inflation Persists

These are the undervalued blue-chip stocks for inflation protection, with the Fed likely to delay the first interest rate cut.

Navigating Interest Rate Speculations and M&A Trends with a Spotlight on Actinium Pharmaceuticals (ATNM)

IMFINZI® (durvalumab) plus chemotherapy doubled overall survival rate at three years for patients with advanced biliary tract cancer in TOPAZ-1 Phase III trial

3 Pharma Stocks That Are Money-Printing Machines in 2024

The economy, and pharma industry, are projected to grow massively. You should invest in these top three pharma stocks.

4 Exceptional Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull Market

Amazing deals can still be found by opportunistic investors, even with the Nasdaq Composite reaching new heights.

Biotech Innovations Paving the Way in Breast Cancer Fight

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:GILD),(NASDAQ:GTHX),(NASDAQ:AZN),(NASDAQ:HOLX) EQNX::TICKER_END

Biotech Innovations Paving the Way in Breast Cancer Fight

/PRNewswire/ -- USA News Group – The American Cancer Society is projecting 2024 to be the first year ever for the US to have more than 2 million new cases,...

FASENRA approved for treatment of children aged 6 to 11 with severe asthma

ENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2 Positive Solid Tumors

ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as first tumor-agnostic HER2-directed therapy for previously treated patients with metastatic HER2-positive solid tumors

IMFINZI® (durvalumab) significantly improved overall survival and progression-free survival for patients with limited-stage small cell lung cancer in ADRIATIC Phase III trial

Datopotamab deruxtecan Biologics License Application accepted in the US for patients with previously treated metastatic HR-positive, HER2-negative breast cancer

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: AdTheorent Holding Company, Inc. (Nasdaq – ADTH), Agiliti, Inc. (NYSE – AGTI), Landos Biopharma, Inc. (Nasdaq – LABP), Fusion Pharmaceuticals Inc. (Nasdaq - FUSN)

VOYDEYA™ approved in the US as add-on therapy to ravulizumab or eculizumab for treatment of extravascular hemolysis in adults with the rare disease PNH

AZN June 21st Options Begin Trading

7 Blue-Chip Stocks That Will Outperform the Dow in the 5 Five Years

These are the blue-chip stocks to outperform Dow in the next five years and represents companies with growth and cash flow visibility.

Bull Market Buys: 3 Dividend Stocks to Own for the Long Run

Invest in stability, dividends, and growth with these three accomplished real estate operators.

Actinium Pharmaceuticals (ATNM): A Prime Buyout Candidate Amidst a Radiopharma Acquisition Wave

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Agiliti, Inc. (NYSE – AGTI), Landos Biopharma, Inc. (Nasdaq – LABP), Fusion Pharmaceuticals Inc. (Nasdaq - FUSN), Kinnate Biopharma Inc. (Nasdaq – KNTE)

ULTOMIRIS® (ravulizumab-cwvz) approved in the US for the treatment of adults with neuromyelitis optica spectrum disorder (NMOSD)

Actinium Pharmaceuticals Inc (NYSE:ATNM) Surges on Analyst Upgrade Amidst Radiopharma Sector Momentum

3 Stagnating Blue-Chip Stocks Ready to Awaken and Soar

These are the stagnating blue-chip stocks to buy at undervalued levels, as they represent fundamentally strong ideas with healthy cash flows.

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Fusion Pharmaceuticals Inc. (Nasdaq - FUSN), Whole Earth Brands, Inc. (Nasdaq – FREE), Kinnate Biopharma Inc. (Nasdaq – KNTE), Societal CDMO Check Corp. (Nasdaq –

Fusion Pharma Stock Nearly Doubles After Scoring $2 Billion AstraZeneca Takeover

The company is working on radiopharmaceuticals treatments for cancer.